Official websites use .gov

A .gov website belongs to an official government organization in the United States.

Secure .gov websites use HTTPS

A lock ( 🔒 ) or https:// means you've safely connected to the .gov website. Share sensitive information only on official, secure websites.

Need Help

Multivalent Anti-VEGF Conjugates for Sustained Treatment of Diabetic Retinopathy

Award Number: R43EY027229
ORGANIZATION: NATIONAL EYE INSTITUTE
OPDIV: NIH
AWARD CLASS: DISCRETIONARY
AWARD ACTIVITY TYPE: SCIENTIFIC/HEALTH RESEARCH (INCLUDES SURVEYS)
PERIOD OF PERFORMANCE START DATE: 09/30/2016
PERIOD OF PERFORMANCE END DATE: 03/29/2018

Group Awards By:

View Award Description

Multivalent Anti-VEGF Conjugates for Sustained Treatment of Diabetic Retinopathy - Project Summary In 2014, approximately 6 million Americans with diabetes were living with the accompanying condition diabetic retinopathy, which is the largest cause of blindness among working-age individuals in the United States. During the progression of DR, ischemic neuronal cells in the retina begin to express vascular endothelial growth factor-A (VEGF-A), leading to macular edema and retinal neovascularization. Inhibition of VEGF-A has become an important approach to ameliorate the sequelae of DR, though current anti-VEGF drugs are rapidly cleared from the vitreous and require frequent administration by intravitreal injection to maintain an effective treatment concentration. Valitor, Inc. is developing protein-polymer therapeutics to overcome the vision- threatening effects of DR. As one example of our patented technology platform, we have conjugated soluble VEGF receptor-1 (sFlt) to linear chains of the natural biopolymer hyaluronic acid (HyA) to generate multivalent conjugates of sFlt (mvsFlt) that are substantially larger than any drugs currently delivered by intravitreal injection. Increasing the size of the mvsFlt conjugates will substantially reduce their clearance rate out of the vitreous, and we have preliminary evidence that mvsFlt conjugates retained within eye can effectively antagonize VEGF-A signaling in the retina, where the VEGF-induced pathologies associated with DR occur. We have designed our mvsFlt therapy to provide sustained anti-VEGF bioactivity following administration by intravitreal injection, which will allow for effective therapy with less frequent treatment sessions. Thus, our strategy for sustained anti-VEGF therapy has the potential to improve both the safety and cost efficacy of DR treatment. Our Phase I objective is to demonstrate that increasing the macromolecular size of mvsFlt conjugates will increase the duration of effective DR treatment. In Specific Aim 1, we will determine how mvsFlt size will affect both its localization within the eye and its ability to provide sustained anti-VEGF therapy. In Specific Aim 2, we will determine the intravitreal half-life of mvsFlt conjugates using a model that will allow direct comparison to published data for clinically available anti-VEGF drugs. Our findings will provide valuable proof-of-mechanism data for further pre-clinical development of our drug product, which we have planned for Phase II of this project.


Issue Date FY	Funding FY	Legal Entity Name	Legal Entity Address	Legal Entity City	Legal Entity State	Legal Entity Zip Code	Legal Entity COUNTY	Legal Entity COUNTRY	Assistance Listing	Award Code	Budget Year	Action Date	Action Type	Action Amount

Issue Date FY: 2022 ( Subtotal = $7,213 )
2022	2017	VALITOR, INC.	2956 SAN PABLO AVE	BERKELEY	CA	94702	ALAMEDA	USA	Vision Research	000	1	9/26/2022	SUPPLEMENT FOR EXPANSION	$7,213
														Subtotal = $7,213

Issue Date FY: 2018 ( Subtotal = -$12,747 )
2018	2017	VALITOR, INC.	820 HEINZ AVE	BERKELEY	CA	94710	ALAMEDA	USA	Vision Research	000	1	8/27/2018	SUPPLEMENT FOR EXPANSION	-$12,747
														Subtotal = -$12,747

Issue Date FY: 2017 ( Subtotal = $32,135 )
2017	2017	VALITOR, INC.	820 HEINZ AVE	BERKELEY	CA	94710	ALAMEDA	USA	Vision Research	000	1	8/18/2017	SUPPLEMENT FOR EXPANSION	$32,135
														Subtotal = $32,135

Issue Date FY: 2016 ( Subtotal = $285,965 )
2016	2016	VALITOR INC	3841 COMPOLINDO DRIVE	MORAGA	CA	94556	CONTRA COSTA	USA	Vision Research	000	1	9/8/2016	NEW	$285,965
														Subtotal = $285,965

Grand Total All Awards = $312,566

Top

All Categories

About

Search

Reports

Data Submission

Award Information

Multivalent Anti-VEGF Conjugates for Sustained Treatment of Diabetic Retinopathy

Award Number: R43EY027229

ORGANIZATION: NATIONAL EYE INSTITUTE

OPDIV: NIH

AWARD CLASS: DISCRETIONARY

AWARD ACTIVITY TYPE: SCIENTIFIC/HEALTH RESEARCH (INCLUDES SURVEYS)

PERIOD OF PERFORMANCE START DATE: 09/30/2016

PERIOD OF PERFORMANCE END DATE: 03/29/2018

Federal Websites

Department of Health & Human Services

HHS Operating Divisions

HHS Staff Divisions

Download A Document Viewer